anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Curcumin is a component of turmeric, a yellow spice from the rhizome of the herb Curcuma longa L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent. Curcumin has a long history of medicinal use for a wide variety of medical conditions. It is insoluble in water but soluble in ethanol, alkalis, glacial acetic acid and chloroform. Oral administration is well tolerated, but bioavailability is very low. Long acting, conserved natural functional group curcumin, of free water solubility, easy digestibility, free intestinal absorption, long serum half-life should help getting the utmost possible beneficial effects of this historical, albeit promising treatment of several acute and chronic illnesses. Natural pure water insoluble curcumin has been converted to a novel, water soluble conserved natural functional group derivatives, with no change to its original active functional natural molecular chemical groups necessary for full biochemical, physiological and pharmacological potencies previously reported for natural curcumin. The novel curcumin derivatives were characterized by IR Spectroscopy, GC/MS, NMR, EM, TLC, Gel Filtration, Continuous Flow Electrophoresis and Isoelectric Focusing whenever applicable. Laboratory animal studies of the novel curcumin derivatives proved that they conserved all the natural curcumin functionality in addition to the novel free water solubility, easy digestibility, free intestinal absorption, long serum half-life besides improved original biochemical, physiological and pharmacological potencies of natural curcumin towards certain pre-studied effects in humans and experimental animal models e.g. erectile dysfunction, diabetes mellitus.
Patients are enrolled sequentially into the next available dosage cohort. Each cohort receives a single dose of tucaresol, is observed for 2 weeks, and then receives 3 alternate-day doses of drug and careful safety monitoring, including 4 weeks follow-up after the final dose. Dose cohorts receive drug sequentially, the lowest-dose cohort receiving the drug first. Dose escalation may not proceed to the next higher-dose cohort until all patients from the prior lower-dose cohort have completed the 4-week follow-up after the multiple dosing, adverse events are within the described bounds, and the FDA has reviewed the safety information from the treated cohort and approved the dose escalation. The drug is administered 4 times within the 8 weeks of the study period. Weekly visits are required. Patients receive financial compensation.
The invention discloses a traditional Chinese medicine dispersible tablet for treating uterine fibroids and a preparation method thereof. The traditional Chinese medicine dispersible tablet is prepared from, by weight, 20-25 parts of herba schizonepetae, 15-20 parts of herba leonuri, 14-18 parts of Barbed Skullcap, 10-15 parts of clam shells, 9-14 parts of pangolin, 5-10 parts of turtle shells, 10-15 parts of Short spike Lagotis, 12-16 parts of suberect spatholobus stems, 8-12 parts of roots of pilose asiabell, 11-17 parts of radix astragali, 16-22 parts of Ligustrum lucidum Ait, 5-10 parts of peach tree roots, 7-13 parts of poria cocos, 10-15 parts of camellia japonica, 12-16 parts of red peony roots, 14-18 parts of Radix Salviae Miltiorrhizae, 15-20 parts of dry rhizome of Sparganium stoloni erum,Buch. -Ham., 10-15 parts of Aeruginous Turmeric Rhizome and 5-10 parts of Sargentodoxa cuneata (Oliv. ) Rehd. et Wils.. The medicines are combined for use, the functions of promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation, nourishing kidneys and yin, replenishing qi, enriching blood, promoting circulation of qi and breaking stagnated blood are achieved, treating and nourishing are conducted at the same time, abdominal mass can be eliminated invisibly when the medicine is taken for a long time, the treatment effect is good, the cure rate is high, no toxic or side effects are caused to human bodies, uterine fibroids are not prone to relapse after being cured, hormone and surgery treatment can be completely replaced, and pain and economic burdens of patients are greatly reduced.
OBJECTIVE: To identify factors affecting the quality of life (QOL) of patients with neurological manifestations of post-COVID syndrome (PCS).
MATERIAL AND METHODS: The study included 60 patients undergoing treatment at the A.Ya. Kozhevnikov Clinic of Nervous Diseases for the underlying disease: tension headaches, migraine, musculoskeletal pain in the neck and back, who had recovered from COVID-19. The main group consisted of 40 patients (average age 47.7±11.43 years). In addition to the manifestations of the underlying disease, they complained of fatigue, decreased performance and concentration, anxiety, memory impairment, low mood, apathy, which arose for the first time during, immediately after, or within 2 months after the coronavirus infection (CI), which met the criteria of the PCS. The comparison group included 20 patients (average age 39±14 years). Patients in this group presented complaints only about their underlying diseases and did not note any peculiarities in their course due to the past CI. For objective assessment of emotional state, we used the Spielberger-Khanin scale, the Beck depression scale, MFI-20, SF-36.
RESULTS: Factors influencing the QoL of patients with PCS are age over 40 years, high trait anxiety, depressive and asthenic syndromes. For the most part, the psychological domain of QOL was lower in patients with PCS, a decrease in vital activity, physical functioning, mental health has also been identified.
CONCLUSION: The results of the study indicate a deterioration in QoL in patients with PCS. In terms of rehabilitation treatment, it is necessary to pay more attention to the treatment of anxiety, depressive and asthenic manifestations.
PURPOSE: A composition containing a Panax ginseng extract and a Crataegis fructus extract is provided to lighten a skin tone and to treat pigmentation with safety in human body. CONSTITUTION: A composition for improving skin condition contains a Panax ginseng extract and a Crataegis fructus extract in a weight ratio of 1:10-10:1. The composition is a food composition, a pharmaceutical composition, or a cosmetic composition. The composition is manufactured in the form of a pill, a powder, a granule, a tablet, a capsule, an external use formulation, a suppository, or a sterilized injection solution. The food composition is selected from the group consisting of a tablet, a capsule, a powder, a granule, a liquid phase, a pill, a beverage, and a tea. [Reference numerals] (AA) Ginseng; (BB) Crataegis fructus; (CC) Mixing ratio 1
PROBLEM TO BE SOLVED: To obtain a dream promoter capable of increasing dreaming frequency by ingesting it before sleeping and enhancing recognition of dream during sleeping when a person is awake by including phosphatidyl-L-serine. SOLUTION: This dream promoter comprises phosphatidyl-L-serine. Although e.g. a phosphatidyl-L-serine obtained by extracting from soybean lecithin, rapeseed lecithin, yolk lecithin, etc., or a transfer type phosphatidyl-L-serine obtained according to phosphatidyl group transfer reaction from phospholipase D by using these lecithins as raw materials can be used as the above phosphatidyl-L- serine, especially a transfer type phosphatidyl-L-serine derived from soybean Lecithin is preferable as the above phosphatidyl-L-serine. Further, a phosphatidyl-L-serine derived from a livestock product of cow, pig, sheep, chicken, fish, etc., or derived from a microorganism such as yeast can also be used. Although the compound can orally or intravenously administered, it is preferable to be administered one or two hours before sleeping.  The daily dose of the compound is preferably about 100-300 mg/adult.
Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed.  These PET  based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided.  In some instances the compounds are developed by derivatizing certain compounds with 18F  in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable. Exemplary compounds include those having the structure (see above formula) wherein n, R, R1, R2, R3, W, X, Y, and Z are as defined in the description.
A Pancreatic Ductal Adenocarcinoma (PDAC) image segmentation method, an electronic device, and a storage medium are provided. In the PDAC image segmentation method, a first model is trained using a first data set; and a second model is trained using a second data set. A third data set is obtained by annotating a to-be-annotated data set using the first model and the second model and a third model is trained using a fourth data set. A training set is obtained by modifying the first data set and the third data set using the third model and a segmentation model is obtained by training an nnUNet using the training set. A to-be-segmented PDAC image is input into the segmentation model, and a segmentation result is obtained. By utilizing the PDAC image segmentation method, a more accurate PDAC image segmentation is achieved.
Research has drawn contradictory conclusions as to whether humans adjust meal size based on meal energy density (ED) or exhibit 'passive overconsumption'. Recent observational research has suggested that meal EDs greater than 1.7-2 kcal/g are compensated for through consumption of smaller meal sizes. We tested the relationship between ED and meal size by examining energy intake of meals at three levels of ED: low (∼1.0 kcal/g), medium (1.7-2.0 kcal/g) and high (>3.0 kcal/g). Two randomised, crossover experiments were conducted with adult participants. In experiment 1 (n = 34, 62% female, mean age 37.4 years), participants were served a lunch including a familiar low, medium or high ED dessert to eat ad libitum. In experiment 2 (n = 32, 66% female, mean age 36.4 years), participants were served a lunch meal manipulated to be low, medium or high ED to eat ad libitum. For experiment 2, later energy intake (post-meal energy intake) was also measured. In experiment 1, participants consumed a similar amount of energy from the low vs. medium ED food. The high ED food was associated with an increased intake of approximately 240 kcals compared to medium (p < 0.001, Cohen's d = 2.31) and low (p < 0.001, Cohen's d = 4.42) ED foods. In experiment 2, there were no significant differences in meal size (grams) between ED meals, resulting in a largely linear relationship between meal ED and energy intake across the three ED conditions ('passive overconsumption'). There were no differences in later energy intake between ED conditions. Contrary to recent suggestions, foods higher in ED were not associated with adjustments to meal size and were associated with increased energy intake across two experiments. Reformulation of foods high in ED may be an effective population level approach to reducing energy intake and obesity. Clinical trial registry number: NCT05744050; https://clinicaltrials.gov/ct2/show/NCT05744050.
The present invention relates to cellulose esters having low hydroxyl content for use in optical applications, such as liquid crystal display (LCD) films. Films made with low hydroxyl levels and a given ratio of non-acetyl ester to hydroxyl level have been found to have low intrinsic birefringence. Therefore, these films can be cast, molded, or otherwise oriented without an appreciable birefringence or optical distortion (i.e. retardation). Such features make these films useful in polarizer, protective, and compensator films as well as molded optical parts, such as lenses. Furthermore, it has also been found that resins of the present invention can also be made to have “+C plate” behavior either by melt or solvent based processing, a characteristic which is not typical of cellulose esters. Such +C behavior allows films to be produced having unique compensatory behavior. Other embodiments of the invention relate to methods melt casting films while minimizing birefringence formation.
Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
FIELD: medicine, surgery. SUBSTANCE: method involves administration to spine interspinous ligament layer at the level L1-L5 the complex medicinal mixture consisting of 32 U of lydazum, 4 mf of dexamethasone, 100 mg of lidocaine, 2 ml of tramal diluted with 40% glucose solution to volume 6 ml. Procedure is repeated 5 times with break for 48 h. Invention promotes to the enhanced arresting lymphatic edemas due to improvement of lymph-venous relations in the lower limbs region. Invention can be used in treatment of lower limbs lymphedema accompanying with development of lymph-venous insufficiency, edemas, chronic pain syndrome. EFFECT: enhanced effectiveness of treatment. 4 tbl
Toxicological studies in dogs on high prolonged doses produced evidence of myocardial damage and failure, and depigmentation of the tapetum lucidum of the eyes, the significance of which is not known. Degenerative changes in the central nervous system, apparently not dose-related, have also been noted in dogs receiving ethambutol hydrochloride over a prolonged period.

In the rhesus monkey, neurological signs appeared after treatment with high doses given daily over a period of several months. These were correlated with specific serum levels of ethambutol hydrochloride and with definite neuroanatomical changes in the central nervous system. Focal interstitial carditis was also noted in monkeys which received ethambutol hydrochloride in high doses for a prolonged period.

When pregnant mice or rabbits were treated with high doses of ethambutol hydrochloride, fetal mortality was slightly but not significantly (P>0.05) increased. Female rats treated with ethambutol hydrochloride displayed slight but insignificant (P>0.05) decreases in fertility and litter size.

In fetuses born of mice treated with high doses of ethambutol hydrochloride during pregnancy, a low incidence of cleft palate, exencephaly and abnormality of the vertebral column were observed. Minor abnormalities of the cervical vertebra were seen in the newborn of rats treated with high doses of ethambutol hydrochloride during pregnancy. Rabbits receiving high doses of ethambutol hydrochloride during pregnancy gave birth to two fetuses with monophthalmia, one with a shortened right forearm accompanied by bilateral wrist-joint contracture and one with hare lip and cleft palate.
The recent recognition of the association of sarcopenia with an increased risk of complications after a surgical procedure calls for rethinking the proper approach of the perioperative care in cancer patients. Sarcopenia is broadly considered in literature according to three different definitions: loss of muscle mass, loss of muscle mass plus reduced muscle function and myosteatosis. The aim of this short review on this issue is to define the excess of risk by type of primary and of surgical procedure, depending on the definition of sarcopenia, to speculate on this association (casual versus causal) and to examine the current therapeutical approaches. The analysis of the data shows that sarcopenia, defined as loss of muscle mass plus reduced muscle function, has the higher predictive power for the occurrence of postoperative complications than the two other definitions, and any definition of sarcopenia works better than the usual indexes or scores of surgical risk. Our analysis supports the concept that: a) sarcopenia is frequently associated with inflammation, but inflammation cannot be considered the only or the absolute cause for sarcopenia, b) sarcopenia is not a simple marker of risk but can have a direct role in the increase of risk. Data on perioperative care of sarcopenic cancer patients are scanty but a correct approach cannot rely on nutritional support alone but on a combined approach of optimized nutrition and exercise, hopefully associated with an anti-inflammatory treatment. This strategy should be applied proactively in keeping with the recent recommendations of the American Society of Clinical Oncology for the medical treatment of advanced cancer patients even if a clear demonstration of effectiveness is still lacking.
<P>PROBLEM TO BE SOLVED: To invalidate prescription order information of medicine for dosing which has becomes unnecessary.  <P>SOLUTION: A prescription order issuing section 11 issues prescription order information and stores it in a prescription order database 10. If the prescription order information is for a medicine for dosing, a corresponding disease name decision section 13 stores a correspondence disease name designated by a user in the prescription order database 10. If an outcome input process is performed in a chart database 2, a prescription order invalidating section 15 obtains outcome information, including a patient ID and the name of the disease of outcome input-processed chart data; extracts prescription order information corresponding to the patient ID and the name of the disease from a prescription order database 2; and urges confirmation of the extracted prescription order. After a confirmation is made by the user, the prescription order information is set to invalidation. A medication indication display processing section 17 displays medication indication, based on the valid prescription order information on a display device 4 at a predetermined date and time.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Cationic polysaccharide derivatives (I) are used to target mineral oxide particles (II) with an average diameter below 0.2 micro m on to the surface of keratinic materials and/or skin, where the compositions undergo phase separation when diluted. Water soluble or dispersible cationic polysaccharide derivatives (I) are used in rinse off aqueous cosmetic compositions to target mineral oxide particles (II) with an average diameter below 0.2 micro m on to the surface of keratinic materials and/or skin. The compositions undergo phase separation when diluted on keratinic materials and/or skin. The composition comprise \- 90 wt.% aqueous phase, and also contain anionic surfactants (III) and amphoteric surfactants (IV). The total amount of (I), (III) and (IV) = 0.5-27 wt.%.  An Independent claim is also included for rinse off aqueous cosmetic compositions for keratinic materials and/or skin, where the compositions contain (I)-(IV), comprise at least 90 wt.% aqueous phase and contain a total of 0.5-27 wt.% (I), (III) and (IV), and where the nature and amounts of (I), (III) and (IV) in the aqueous phase are such that the compositions undergo phase separation when diluted.
Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
PURPOSE: Frailty is a syndrome caused by multiple factors and can lead to serious consequences for middle-aged and elderly patients with colorectal cancer. However, few studies have comprehensively explored predictors of frailty and built predictive models. Therefore, our aim is to develop and evaluate a predictive model for frailty in middle-aged and elderly patients with colorectal cancer.
METHODS: From July 2023 to February 2024, a total of 502 middle-aged and elderly patients with colorectal cancer participated in this survey. Patients were randomly divided into training and validation groups in a 7:3 ratio. Univariate and multiple logistic regression analysis were employed to identify potential predictors of frailty in these patients. A nomogram was constructed based on the predictive factors, and the model underwent internal validation.
RESULTS: In the training cohort, logistic regression revealed that self-perceived health, chronic pain, loneliness, depression, and health-promoting lifestyle were independent predictors of frailty. The Areas Under the Curve (AUC) of the training and validation groups were 0.845 and 0.851, respectively. The calibration curve of the nomogram demonstrated good consistency between predicted and actual probabilities. Decision curve analysis revealed good clinical benefit.
CONCLUSIONS: This study established a predictive model with satisfactory predictive ability, providing empirical evidence for the early detection and intervention of frailty in middle-aged and elderly patients with colorectal cancer. The nomogram model has significant potential for clinical application, as it can be integrated into routine oncology practice to identify high-risk patients early, allowing for timely and individualized interventions to improve patient outcomes.
Deletions of the long arm of chromosome 20 (20q) are rare, with only 16 reported patients displaying a proximal interstitial 20q deletion. A 1.62 Mb minimal critical region at 20q11.2, encompassing three genes GDF5, EPB41L1, and SAMHD1, is proposed to be responsible for this syndrome. The leading clinical features include growth retardation, intractable feeding difficulties with gastroesophageal reflux, hypotonia and psychomotor developmental delay. Common facial dysmorphisms including triangular face, hypertelorism, and hypoplastic alae nasi were additionally reported. Here, we present the clinical and molecular findings of five new patients with proximal interstitial 20q deletions. We analyzed the phenotype and molecular data of all previously reported patients with 20q11.2q12 microdeletions, along with our five new cases. Copy number variation analysis of patients in our cohort has enabled us to identify the second critical region in the 20q11.2q12 region and redefine the first region that is initially identified. The first critical region spans 359 kb at 20q11.2, containing six MIM genes, including two disease-causing genes, GDF5 and CEP250. The second critical region spans 706 kb at 20q12, encompassing four MIM genes, including two disease-causing genes, MAFB and TOP1. We propose GDF5 to be the primary candidate gene generating the phenotype of patients with 20q11.2 deletions. Moreover, we hypothesize TOP1 as a potential candidate gene for the second critical region at 20q12. Of note, we cannot exclude the possibility of a synergistic role of other genes involved in the deletion, including a contiguous gene deletion syndrome or position effect affecting both critical regions. Further studies focusing on patients with proximal 20q deletions are required to support our hypothesis.
The present invention relates to the field of biomedicine. Disclosed are a brain tumor-targeting polypeptide, a derivative thereof and an application thereof. Specifically disclosed is use of the polypeptide in the preparation of a brain tumor-targeting drug or a detection reagent. The polypeptide is selected from metabolitin or osteocalcin. Also disclosed is a derivative of the polypeptide. The derivative is a product obtained by modifying the polypeptide by a terminus or a side chain. The polypeptide molecules can enter brain tissue across the blood-brain barrier to be combined with a brain tumor area, and the polypeptide provides a specific targeted delivery means for diagnosis and treatment of brain tumor diseases.